Journal of Clinical Oncology, Vol 21, Issue 12
(June), 2003: 2407-2414
© 2003 American Society for Clinical Oncology
Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002
Andrés J.M. Ferreri,
Lauren E. Abrey,
Jean-Yves Blay,
Bettina Borisch,
Jacob Hochman,
Edward A. Neuwelt,
Joachim Yahalom,
Emanuele Zucca,
Franco Cavalli,
James Armitage,
Tracy Batchelor
From the Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy; Departments of Neurology and Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Neurology and Neurosurgery, Oregon Health & Science University, Portland, OR; College of Medicine, University of Nebraska Medical Center, Omaha, NE; Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, MA; Unité Cytokines et Cancers, Hôpital E. Herriot & Centre Léon Bérard, Lyon, France; Department of Pathology, University of Geneva, Geneva; Oncology Institute of Southern Switzerland, Division of Medical Oncology, Ospedale San Giovanni, Bellinzona, Switzerland; and Department of Cell and Animal Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
Address reprint requests to Andrés J.M. Ferreri, MD, Department of Radiochemotherapy, San Raffaele H Scientific Institute, Via Olgettina 60, 20132, Milan, Italy; email: andres.ferreri{at}hsr.it.
Under the sponsorship of the International Extranodal Lymphoma Study Group, a Multidisciplinary Workshop on primary CNS lymphoma (PCNSL) with over 50 participants from Europe, North America, Israel, and Australia was held as part of the Eighth International Conference on Malignant Lymphoma in Lugano, Switzerland (June 12 to 15, 2002). The main purposes of the Workshop were to exchange the latest scientific information, to analyze methodologic issues in the design of clinical trials, to reach a consensus on treatment recommendations and prognostic factors, to discuss clinical and molecular targets for future studies, and to establish an international collaborative group to conduct laboratory and clinical investigations in PCNSL. This article summarizes the contents of the Workshop, analyzes the current knowledge on the most relevant biologic and clinical issues in PCNSL, and focuses on fundamental challenges to be addressed in future studies.
The Workshop on Primary CNS Lymphomas (Lugano, Switzerland, June 11, 2002) has been supported by an educational grant of the European School of Oncology and, in part, by the Swiss Cancer League.
This article has been cited by other articles:

|
 |

|
 |
 
R. Hassan, C. G. Stefanoff, F. Felisbino, M. H. M. Barros, I. R. Zalcberg, C. E. Klumb, R. S. Bigni, and H. N. Seuanez
Second Epstein-Barr Virus-Associated Burkitt's Lymphoma of the CNS in a Child With Progressive Renal Failure
J. Clin. Oncol.,
June 20, 2008;
26(18):
3085 - 3087.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. D. Doolittle, L. E. Abrey, T. N. Shenkier, S. Tali, J. E.C. Bromberg, E. A. Neuwelt, C. Soussain, K. Jahnke, P. Johnston, G. Illerhaus, et al.
Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
Blood,
February 1, 2008;
111(3):
1085 - 1093.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Batchelor and J. S. Loeffler
Primary CNS Lymphoma
J. Clin. Oncol.,
March 10, 2006;
24(8):
1281 - 1288.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. DeAngelis and F. M. Iwamoto
An Update on Therapy of Primary Central Nervous System Lymphoma
Hematology,
January 1, 2006;
2006(1):
311 - 316.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Domhan, C. Morath, P. Schnulle, R. Waldherr, and M. Zeier
A generalized seizure in a renal allograft recipient
Nephrol. Dial. Transplant.,
April 1, 2005;
20(4):
834 - 836.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Neuwelt, P. E. Guastadisegni, P. Varallyay, and N. D. Doolittle
Imaging Changes and Cognitive Outcome in Primary CNS Lymphoma after Enhanced Chemotherapy Delivery
AJNR Am. J. Neuroradiol.,
February 1, 2005;
26(2):
258 - 265.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. T. Batchelor, B. R. Buchbinder, and N. L. Harris
Case 1-2005 - A 35-Year-Old Woman with Difficulty Walking, Headache, and Nausea
N. Engl. J. Med.,
January 13, 2005;
352(2):
185 - 194.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M.P. Omuro, L. M. DeAngelis, J. Yahalom, and L. E. Abrey
Chemoradiotherapy for primary CNS lymphoma: An intent-to-treat analysis with complete follow-up
Neurology,
January 11, 2005;
64(1):
69 - 74.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. P. O'Neill
Neurocognitive outcomes in primary CNS lymphoma (PCNSL)
Neurology,
February 24, 2004;
62(4):
532 - 533.
[Full Text]
[PDF]
|
 |
|
|